This preprint develops a mechanistic hypothesis to explain a documented pharmacovigilance asymmetry: Gardasil (HPV4) generates 389 POI-related reports in VAERS with positive Bayesian signal detection, versus 2 for Cervarix (HPV2) with no detectable signal — despite both vaccines sharing HPV 16/18 L1 VLP antigen, and Cervarix containing 2.2× more aluminum in a more immunostimulatory formulation (AS04 + TLR4 agonist). We propose that polysorbate 80 (PS80, 50 µg/dose in Gardasil, absent in Cervarix) acts as a vectorizing excipient via apolipoprotein E (ApoE) plasma protein corona formation, enabling LDLR-mediated transcytosis across the blood-follicle barrier and autonomic microvasculature. This mechanism delivers highly immunogenic HPV L1 VLPs to immunologically privileged compartments, where molecular mimicry with zona pellucida ZP3 epitopes triggers autoimmune follicular depletion (POI), and cross-reactive antibodies against adrenergic and muscarinic receptors produce autonomic dysfunction (POTS). The co-occurrence of POI and POTS in the same post-Gardasil patients — an unexplained epidemiological pattern — is reframed as the predictable consequence of systemic antigen distribution under plasma corona routing, with organ specificity determined by barrier accessibility and cross-reactive antigen distribution. The analysis is integrated into a two-level iatrogenic autoimmunity framework (Level 1: excipient initiators; Level 2: antigenic specifiers) and includes six falsifiable predictions. The pre-licensure trial design — using AAHS or PS80-containing carrier solution as "placebo" — is identified as an architectural limitation that prevents detection of excipient-mediated adverse effects. This preprint is part of a series on excipient-mediated iatrogenic autoimmunity. Correspondence: juanfgaston@gmail.com
Añaños et al. (Sat,) studied this question.